These data suggest that the usefulness of VEGF-A as a blood marker for predicting the efficacy of anti-PD-1/PD-L1 antibody therapy in patients with NSCLC depends on the sample type, such as serum or plasma. This evidence concerns the gene CD274 and non-small cell lung carcinoma.